Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KDM5A/B contribute to HIV-1 latent infection and survival of HIV-1 infected cells

24 Jun 2024

Abstract excerpt

Combinational antiretroviral therapy (cART) suppresses human immunodeficiency virus type 1 (HIV-1) viral replication and pathogenesis in acquired immunodeficiency syndrome (AIDS) patients. However, HIV-1 remains in the latent stage of infection by suppressing viral transcription, which hinders an HIV-1 cure. One approach for an HIV-1 cure is the "shock and kill" strategy. The strategy focuses on reactivating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS Research and Interventions
Share to HIV Research and Treatment
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38925368
DOI: 10.1016/j.antiviral.2024.105947

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KDM5A/B contribute to HIV-1 latent infection and survival of HIV-1 infected cellsPMID 38925368Read ↗

KDM5A/B promotes HIV-1 latency and KDM5 inhibitors promote HIV-1 lytic reactivationSemantic proximity Read ↗

Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?Semantic proximity Read ↗

Inhibition of ALKBH5 demethylase of m6A pathway potentiates HIV-1 reactivation from latencySemantic proximity Read ↗

Epigenetic control of HIV-1 post integration latency: implications for therapySemantic proximity Read ↗

Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a CureSemantic proximity Read ↗

A New Small-Molecule Compound, Q308, Silences Latent HIV-1 Provirus by Suppressing Tat- and FACT-Mediated TranscriptionSemantic proximity Read ↗

A broad drug arsenal to attack a strenuous latent HIV reservoirSemantic proximity Read ↗

Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategiesSemantic proximity Read ↗

Epigenetic Suppression of HIV in Myeloid Cells by the BRD4-Selective Small Molecule Modulator ZL0580Semantic proximity Read ↗

Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication.Semantic proximity Read ↗

Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoirSemantic proximity Read ↗

Epigenetically repressing human cytomegalovirus lytic infection and reactivation from latency in THP-1 model by targeting H3K9 and H3K27 histone demethylasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.